G, B., CG, C., D, M., M, M., D, P., F, A., . . . F, P. (2024). Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: The observational, multicenter, prospective, phase IV CLADFIT-MS study. Frontiers in neurology, 15, 1422078. https://doi.org/10.3389/fneur.2024.1422078
Chicago Style (17th ed.) CitationG, Borriello, Chisari CG, Maimone D, Mirabella M, Paolicelli D, Assogna F, Caradonna S, and Patti F. "Cladribine Effects on Patient-reported Outcomes and Their Clinical and Biometric Correlates in Highly Active Relapsing Multiple Sclerosis at First Switch: The Observational, Multicenter, Prospective, Phase IV CLADFIT-MS Study." Frontiers in Neurology 15 (2024): 1422078. https://doi.org/10.3389/fneur.2024.1422078.
MLA (9th ed.) CitationG, Borriello, et al. "Cladribine Effects on Patient-reported Outcomes and Their Clinical and Biometric Correlates in Highly Active Relapsing Multiple Sclerosis at First Switch: The Observational, Multicenter, Prospective, Phase IV CLADFIT-MS Study." Frontiers in Neurology, vol. 15, 2024, p. 1422078, https://doi.org/10.3389/fneur.2024.1422078.
